Shortage of Carbagen® 200 and 400mg immediate release (IR) and 200 and 400mg prolonged release (PR) tablets

Date: 1st February 2019

Description of product affected

Carbagen tablets are licensed for the treatment of epilepsy (generalised tonic–clonic and partial seizures), paroxysmal pain of trigeminal neuralgia, and prophylaxis of manic-depressive psychosis in patients unresponsive to lithium therapy.¹

Background

There is a shortage 200 and 400mg immediate release (IR) and 200 and 400 mg prolonged release (PR) tablets (the 100mg IR tablets are no longer marketed).

The PR 200mg and 400mg tablets are expected back in stock in late 2019, the IR 200mg tablets end of second quarter 2019 and IR 400mg tablets in late 2019.

Alternative agents and management options

The only other brand of carbamazepine tablets available is Tegretol (100, 200 and 400mg IR and 200 and 400mg PR).² Novartis have confirmed that there is sufficient stock of Tegretol to cover the shortfall of Carbagen.*

The MHRA has classified carbamazepine as a Category 1 antiepileptic drug, which means there are clear indications that clinically relevant differences between different manufacturers’ products might occur, even when the pharmaceutical forms are the same and bioequivalence has been shown. Therefore the patient should be maintained on a specific manufacturer’s product.³ However, in the event of a shortage of a product, it is not possible to maintain the patient on their previous preparation; all product switches must be carried out with care and close monitoring, and where possible, patients should be maintained from then onwards on a single manufacturer’s product.⁴

Managing existing stock

In order to preserve any stock of this brand for patients already on it for epilepsy:

- No new patients should be started on Carbagen until the shortage has resolved.
- Remaining stock should not be used for prescriptions written generically without confirmation patient is already on this brand for epilepsy.
- Patients with optimal seizure control (i.e. seizure-free or their seizure frequency has been markedly reduced) should be prioritised, particularly where there is a history of good seizure control and where the recurrence of a seizure could lead to socio-economic harm (e.g. loss of a driving license).
- People with epilepsy who are most anxious/vulnerable to change may also need to be prioritised.

¹ The MHRA has classified carbamazepine as a Category 1 antiepileptic drug, which means there are clear indications that clinically relevant differences between different manufacturers’ products might occur, even when the pharmaceutical forms are the same and bioequivalence has been shown. Therefore the patient should be maintained on a specific manufacturer’s product. However, in the event of a shortage of a product, it is not possible to maintain the patient on their previous preparation; all product switches must be carried out with care and close monitoring, and where possible, patients should be maintained from then onwards on a single manufacturer’s product.

² Novartis have confirmed that there is sufficient stock of Tegretol to cover the shortfall of Carbagen.

³ The MHRA has classified carbamazepine as a Category 1 antiepileptic drug, which means there are clear indications that clinically relevant differences between different manufacturers’ products might occur, even when the pharmaceutical forms are the same and bioequivalence has been shown. Therefore the patient should be maintained on a specific manufacturer’s product. However, in the event of a shortage of a product, it is not possible to maintain the patient on their previous preparation; all product switches must be carried out with care and close monitoring, and where possible, patients should be maintained from then onwards on a single manufacturer’s product.

⁴ The MHRA has classified carbamazepine as a Category 1 antiepileptic drug, which means there are clear indications that clinically relevant differences between different manufacturers’ products might occur, even when the pharmaceutical forms are the same and bioequivalence has been shown. Therefore the patient should be maintained on a specific manufacturer’s product. However, in the event of a shortage of a product, it is not possible to maintain the patient on their previous preparation; all product switches must be carried out with care and close monitoring, and where possible, patients should be maintained from then onwards on a single manufacturer’s product.
Non-epilepsy uses of antiepileptic drugs do not generally have significant consequences following minor changes in dose so switching is unlikely to cause problems.\(^5\)

**Switching patients with epilepsy to Tegretol**

- It is important the transition is carefully discussed with the patient so that they are aware of the change and the potential risk, without creating excess anxiety or alarm.
- Patients should be switched to the same dose and release profile of Tegretol.
- Patient/carers should be advised to report any problems with seizure control after a switch; seizure diaries may be helpful to identify any change in seizure patterns, particularly in complex cases (who may have diaries already).
- Patient/carers should be reminded of the signs of toxicity and advised to report any concerns (e.g. drowsiness, slurred speech, ataxia, hallucinations, nausea, vomiting, tremors, seizures, oliguria, blurred vision, bullous skin formations.\(^6\)).

Advice should be sought from specialist pharmacists/neurologists if there are concerns about switching in complex cases or if any problems arise after switching. Carbamazepine dosing is primarily guided by clinical response, plasma levels are not part of routine practice, and should not be undertaken without specialist advice to enable appropriate interpretation and management recommendations to be made.

*It is likely some Carbagen products are already out of stock and due to the length of time these products will be out of stock, it is anticipated that all patients on Carbagen will need to be switched to Tegretol.*

**References**

2. Carbamazepine SPCs accessed via emc, 09 Jan 2019: [https://www.medicines.org.uk/emc/search?q=%22carbamazepine%22](https://www.medicines.org.uk/emc/search?q=%22carbamazepine%22)
4. The NEWT Guidelines. Carbamazepine monograph, updated November 2018
5. UKCPA Neurosciences Group/ Pharmaceutical Market Support Group (PMSG): Generics Sub-Group. The Use of Generic Anti-Epileptics Drugs in Patients with Epilepsy: consensus view; November 2012
Acknowledgements

- Shelley Jones, Lead Clinical Pharmacist, Neurosciences, King's College Hospital NHS Foundation Trust
- Carl Holvey, Clinical Pharmacy Services Lead, Bart's Health NHS Trust
- Jin-Jin Ward, Senior Pharmacist – Mental Health, Lewisham and Greenwich NHS Trust
- Petrina Douglas-Hall, Medicines Information Manager, South London and Maudsley NHS Foundation Trust
- Trinh Huynh, Highly Specialist Pharmacist – Paediatrics, Evelina London Children’s Hospital

Original document prepared by:
Yuet Wan, London and South East Regional Medicines Information, Guy’s and St Thomas’ NHS Foundation Trust, 22nd Jan 2019, email: medicinesinformation@gstt.nhs.uk

Document modified by and for all correspondence please contact:
Cambridgeshire and Peterborough CCG Medicines Optimisation Team. 1st February 2019; email: CAPCCG.prescribingpartnership@nhs.net

Disclaimer: This memo can be adapted for local use. The content does not reflect national guidance. Some of this memo is based on clinical opinion from practitioners. Users should bear this in mind in deciding whether to base their policy on this document. Individual trusts should ensure that procedures for unlicensed medicines are followed where a foreign import drug is required in the interim. Any decision to prescribe off-label must take into account the relevant GMC guidance and NHS Trust governance procedures for unlicensed medicines. Prescribers are advised to pay particular attention to the risks associated with using unlicensed medicines or using a licensed medicine off-label.